- Capricor Therapeutics (NASDAQ:CAPR) announced the publication of a preclinical study online in bioRxiv and explored Capricor’s proprietary StealthX exosome platform’s therapeutic potential, generating two vaccine candidates (STX-S and STX-N).
- The vaccines independently and in combination (STX-S+N) induced a strong immune response against two SARS-CoV-2 proteins, spike and nucleocapsid.
- Results showed that this multivalent, protein-based vaccine candidate has the potential to achieve potent, longer-lasting immunization, broaden reactivity and improve T-cell response with only nanograms of protein without any adjuvant.
- The data from this study suggests that StealthX could deliver a more potent vaccine with broader immunity than is currently available by combining the advantages of both mRNA and recombinant protein vaccines into a potentially superior, low-dose vaccine.
- Capricor said it had halted work on the exosome-based jab in March due to the “current availability of vaccines for” COVID-19. Instead, the Company will focus its resources on CAP-1002 for Duchenne muscular dystrophy.
- Capricor also tested CAP-1002 in patients hospitalized with severe COVID-19 who are on supplemental oxygen. Overall mortality in the study was 20%, with six deaths in the placebo group and five in the CAP-1002 group.
- Price Action: CAPR shares are up 4.03% at $4.13 on the last check Thursday.
Investor Optimism Improves Ahead Of Inflation Data
The CNN Money Fear and Greed index showed some improvement in overall sentiment among U.S. investors on Tuesday.
U.S. stocks closed higher on Tuesday ahead of this week’s key inflation data. The consumer price index is scheduled for release on Wednesday, while the producer price index will be released on Thursday.
